Additionally, studies comparing the efficacy of faricimab with other anti-VEGF agents in a group of patients with expected high activity of both the VEGF and Ang-2/Tie-2 pathways, e.g., in a population with comorbid diabetes and nAMD, may be of particular interest. This evidence concerns the gene TEK and diabetes mellitus.